CD206⁺ TAM depletion attenuates T cell – mediated tumor control in an immune-responsive tumor model. (A) Representative time course of MC38chOVA tumor size with or without adoptive transfer of OT-I T cells. (B) CD206 expression in monocytes gated by MHCII expression and TAMs gated by VCAM1 and CD127, as shown in Fig. 1 B, but in MC38chOVA tumors. (C and D) (C) Distribution of Venus reporter expressing cells in a typical MC38chOVA tumor at day 18 (d18) and (D) corresponding distribution segregated by CD206 expression. (E) Schematic representation of the experimental setup for early and late CD206⁺ TAM depletion in MC38chOVA tumors using Csf1r^Cre; Mrc1^{LSL-Venus-DTR} mice. (F–H and J–L) Relative abundance of (F and J) CD206⁺ and CD206⁻ TAMs, (G and K) cDC1s. and (H and L) CD8 T cells as a percentage of CD45⁺ cells with late and early depletion regimens respectively. (I and M) Representative flow cytometry plots showing CD206 versus MHCII expression in different myeloid subsets in WT (red) and DTR (blue) mice in the (I) late and (M) early depletion regimens. (N and O) %CXCL9⁺ of TAMs and (O) %C1q TAMs (gated as VCAM1^hiCD127^lo) of CD45 in WT and DTR mice with early depletion. (P) Tumor growth kinetics of MC38chOVA tumors in WT and DTR mice with DTx treatment beginning 2 days after OT-I adoptive transfer at day 0; bar graphs show mean ± SEM; data are representative of at least two independent experiments, each with at least three biological replicates per group for B–O, and with at least five biological replicates per group for A and P. **P < 0.01, *P < 0.05, ns = no significance by Student’s t test or Mann–Whitney U test or unpaired t tests.